MyAV范

Our new partnership enables MyAV范 to develop and distribute an imaging agent, furthering the understanding and treatment of neurodegenerative disease.

Cerveau develops diagnostics and technology to treat patients with neurodegenerative disorders. MyAV范 is a leading centre for the production and application of imaging biomarkers for use in clinical research. Under this partnership, MyAV范 will manufacture and distribute the imaging agent called [¹⁸F]MK-6240.听

MyAV范 will use [¹⁸F]MK-6240 in clinical studies to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs are the hallmark of several neurodegenerative diseases, including Alzheimer鈥檚 Disease. The MyAV范 Centre for Radiopharmaceutical Chemistry will be the first UK site to distribute [¹⁸F]MK-6240, which is produced according to good manufacturing practices (GMP). It will then be provided to the MyAV范 Dementia Research Centre and the wider biomedical research community.

Rick Hiatt, President and CEO of Cerveau Technologies said: 鈥淲e are enthusiastic about working with the team at MyAV范 and making the tracer broadly accessible for investigations in the UK. We believe that the expertise and collaboration we have seen from the MyAV范 team is a great indication of a promising collaboration between Cerveau and MyAV范 to enable broad access for scientific research and clinical trial support.鈥�

Further reading
MyAV范 News story: MyAV范 announces new collaboration with Cerveau Technologies